Long-Term Efficacy and Safety Data on PP Treatments

EP: 1.Overview of PP

EP: 2.The Role of Physician Assistants in PP Management

EP: 3.Factors to Consider when Treating PP

EP: 4.Impact of PP Comorbidities

EP: 5.Treatment Options for Pregnant People With PP

EP: 6.Caring for Pediatric Patients With PP

EP: 7.PP Treatment Selection: Best Practices

EP: 8.Drug Class Considerations for Patients With PP

EP: 9.PP Treatment Efficacy

EP: 10.Topical Therapy Options for PP

EP: 11.Plaque Psoriasis Treatment Selection Considerations

EP: 12.Aryl Hydrocarbon Receptor Treatments for PP

EP: 13.Tapinarof Selectivity and Mechanism of Action for PP Treatment

Now Viewing

EP: 14.Long-Term Efficacy and Safety Data on PP Treatments

EP: 15.Identifying the Remittive Effect in PP Patients

EP: 16.Positioning Aryl Hydrocarbon Receptor Agonists in PP Treatment Regimens

EP: 17.Key Takeaways for the Management of PP

EP: 18.Considering Plaque Psoriasis Comorbidities in Treatment Plans

Transcript

Lauren Miller, MPAS, PA-C: There aren’t head-to-head trials with tapinarof and roflumilast, but let’s talk about long-term safety data. When I look at a clinical trial, and when a patient comes in, I’m not looking at the short term. Obviously, I want to get them better quickly, but I’m thinking long term. This is a long-term disease, and I don’t want to have to take somebody off therapy if I can help it. The goal is to keep somebody on therapy. If it’s effective, we want that efficacy to last and be durable. Let’s talk about long-term efficacy and how that plays into how we prescribe a product. You have experience with tapinarof. Do you have experience with roflumilast?

TJ Chao, MPAS, PA-C: Yes, I do. I have about equal or slightly less experience.

Lauren Miller, MPAS, PA-C: With tapinarof they’ve got around 52 weeks of long-term safety data, and it appears that that efficacy is maintained throughout. From their primary end point to the end of the 52-week long-term extension study, that durability of response was maintained. That gives me confidence when I’m prescribing it. I can tell my patient, “If we’re able to get you clear, the odds are that you’re going to maintain that.” Do you feel like that is the same with roflumilast from what you’re seeing?

TJ Chao, MPAS, PA-C: It’s similar, but what’s different are some of the data that you have with tapinarof that show a remittive effect. Patients in the long-term extension PSOARING 3 trial were able to stop therapy eventually and go a long time, in some cases 4 months, without any return of disease. That’s landmark, and it’s completely different from what we’ve seen before. We’ve never had data to show that until now.

Lauren Miller, MPAS, PA-C: They actually have that in their label.

TJ Chao, MPAS, PA-C: Correct.

Transcript edited for clarity.